# GC012F Injection in Refractory Idiopathic Inflammatory Myopathy

> **NCT07086404** · EARLY_PHASE1 · RECRUITING · sponsor: **Daishi Tian** · enrollment: 12 (estimated)

## Conditions studied

- Idiopathic Inflammatory Myopathy (IIM)

## Interventions

- **DRUG:** GC012F Injection infusion

## Key facts

- **NCT ID:** NCT07086404
- **Lead sponsor:** Daishi Tian
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2027-09-15
- **Final completion:** 2029-09-15
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- AstraZeneca Global R&D (China) Co., Ltd.
- Gracell Biotechnologies (Shanghai) Co., Ltd.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07086404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07086404, "GC012F Injection in Refractory Idiopathic Inflammatory Myopathy". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07086404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*